{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T22:54:13Z","timestamp":1784415253704,"version":"3.55.0"},"reference-count":48,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"42","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1097\/md.0000000000001858","type":"journal-article","created":{"date-parts":[[2015,10,24]],"date-time":"2015-10-24T12:48:26Z","timestamp":1445690906000},"page":"e1858","source":"Crossref","is-referenced-by-count":32,"title":["Putative Role of Serum Amyloid-A and Proinflammatory Cytokines as Biomarkers for Behcet's Disease"],"prefix":"10.1097","volume":"94","author":[{"given":"Giuseppe","family":"Lopalco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orso Maria","family":"Lucherini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Vitale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosaria","family":"Talarico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Lopalco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Galeazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Lapadula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Cantarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florenzo","family":"Iannone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-85-20210309","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.rdc.2013.02.010","article-title":"Behcets syndrome.","volume":"39","author":"Hatemi","year":"2013","journal-title":"Rheum Dis Clin North Am"},{"key":"R2-85-20210309","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.autrev.2014.08.008","article-title":"Effectiveness and tuberculosis-related safety profile of interleukin-1 blocking agents in the management of Behcets disease.","volume":"14","author":"Cantarini","year":"2015","journal-title":"Autoimmun Rev"},{"key":"R3-85-20210309","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1136\/ard.60.11.996","article-title":"Behcets disease: infectious aetiology, new autoantigens, and HLA-B51.","volume":"60","author":"Direskeneli","year":"2001","journal-title":"Ann Rheum Dis"},{"key":"R4-85-20210309","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s00296-007-0470-y","article-title":"Differential expression of toll-like receptor 6 on granulocytes and monocytes implicates the role of microorganisms in Behcets disease etiopathogenesis.","volume":"28","author":"Yavuz","year":"2008","journal-title":"Rheumatol Int"},{"key":"R5-85-20210309","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.1365-2249.2008.03626.x","article-title":"Involvement of innate immunity in the pathogenesis of intestinal Behcets disease.","volume":"152","author":"Nara","year":"2008","journal-title":"Clin Exp Immunol"},{"key":"R6-85-20210309","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1080\/030097402320318387","article-title":"Cytokine profile in Behcets disease patients. Relationship with disease activity.","volume":"31","author":"Hamzaoui","year":"2002","journal-title":"Scand J Rheumatol"},{"key":"R7-85-20210309","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/S0181-5512(06)73762-7","article-title":"Production of Th1Th2 cytokines and nitric oxide in Behcets uveitis and idiopathic uveitis.","volume":"29","author":"Guenane","year":"2006","journal-title":"J Fr Ophtalmol"},{"key":"R8-85-20210309","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1002\/art.20334","article-title":"Involvement of chemokines and Th1 cytokines in the pathogenesis of mucocutaneous lesions of Behcets disease.","volume":"50","author":"Ben Ahmed","year":"2004","journal-title":"Arthritis Rheum"},{"key":"R9-85-20210309","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/icb.2010.158","article-title":"CXCR3 ligands: redundant, collaborative and antagonistic functions.","volume":"89","author":"Groom","year":"2011","journal-title":"Immunol Cell Biol"},{"key":"R10-85-20210309","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jneuroim.2003.08.040","article-title":"Cytokines and chemokines in neuro-Behcets disease compared to multiple sclerosis and other neurological diseases.","volume":"145","author":"Saruhan-Direskeneli","year":"2003","journal-title":"J Neuroimmunol"},{"key":"R11-85-20210309","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/j.1365-4632.2004.02184.x","article-title":"Serum interleukin-8 as a serologic marker of activity in Behcets disease.","volume":"44","author":"Gur-Toy","year":"2005","journal-title":"Int J Dermatol"},{"key":"R12-85-20210309","first-page":"249","article-title":"IL-8 producing cells in patients with Behcets disease.","volume":"18","author":"Mantas","year":"2000","journal-title":"Clin Exp Rheumatol"},{"key":"R13-85-20210309","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s004030000128","article-title":"Adamantiades-Behcets disease: interleukin-8 is increased in serum of patients with active oral and neurological manifestations and is secreted by small vessel endothelial cells.","volume":"292","author":"Zouboulis","year":"2000","journal-title":"Arch Dermatol Res"},{"key":"R14-85-20210309","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1007\/s004030050219","article-title":"The demonstration of serum interleukin-8 and superoxide dismutase in Adamantiades-Behcets disease.","volume":"289","author":"Wang","year":"1997","journal-title":"Arch Dermatol Res"},{"key":"R15-85-20210309","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1136\/ard.55.2.128","article-title":"Neutrophil adhesion to endothelial cells and factors affecting adhesion in patients with Behcets disease.","volume":"55","author":"Sahin","year":"1996","journal-title":"Ann Rheum Dis"},{"key":"R16-85-20210309","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1159\/000018426","article-title":"Adamantiades-Behcets disease: serum IL-8 is a more reliable marker for disease activity than C-reactive protein and erythrocyte sedimentation rate.","volume":"201","author":"Katsantonis","year":"2000","journal-title":"Dermatology"},{"key":"R17-85-20210309","first-page":"1332","article-title":"Changes of neutrophil migration without modification of in vitro metabolism and adhesion in Behcets disease.","volume":"24","author":"Carletto","year":"1997","journal-title":"J Rheumatol"},{"key":"R18-85-20210309","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1365-4362.1986.tb02232.x","article-title":"Behcets disease. Relation of serum C-reactive protein and erythrocyte sedimentation rates to disease activity.","volume":"25","author":"Muftuoglu","year":"1986","journal-title":"Int J Dermatol"},{"key":"R19-85-20210309","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1046\/j.1432-1327.1999.00657.x","article-title":"Serum amyloid A, the major vertebrate acute-phase reactant.","volume":"265","author":"Uhlar","year":"1999","journal-title":"Eur J Biochem"},{"key":"R20-85-20210309","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1007\/s10067-014-2555-9","article-title":"Serum amyloid-A in Behcets disease.","volume":"33","author":"Vitale","year":"2014","journal-title":"Clin Rheumatol"},{"key":"R21-85-20210309","first-page":"1078","article-title":"International Study Group for Behcets Disease.","volume":"335","year":"1990","journal-title":"Lancet"},{"key":"R22-85-20210309","first-page":"w13580","article-title":"AA amyloidosis: basic knowledge, unmet needs and future treatments.","volume":"142","author":"Obici","year":"2012","journal-title":"Swiss Med Wkly"},{"key":"R23-85-20210309","first-page":"7","article-title":"Serum cytokine profiles in Behcets disease: is there a role for IL-15 in pathogenesis Immunol L","volume":"121","author":"Curnow","year":"2008","journal-title":"ett"},{"key":"R24-85-20210309","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1365-2230.2004.01684.x","article-title":"Serum interleukin 18 and tumour necrosis factor-alpha levels are increased in Behcets disease.","volume":"30","author":"Oztas","year":"2005","journal-title":"Clin Exp Dermatol"},{"key":"R25-85-20210309","first-page":"545","article-title":"Serum interleukin-18 levels in patients with Behcets disease.","volume":"26","author":"Musabak","year":"2006","journal-title":"Is its expression associated with disease activity or clinical presentations Rheumatol Int"},{"key":"R26-85-20210309","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.autrev.2014.12.009","article-title":"IFN- induces IL-10 production and tilt the balance between Th1 and Th17 in Behcet disease.","volume":"14","author":"Touzot","year":"2015","journal-title":"Autoimmun Rev"},{"key":"R27-85-20210309","first-page":"S37","article-title":"Pronounced interferon-alpha production from plasmacytoid dendritic cells in patients with Behcets disease following CpG D ODN stimulation.","volume":"27","author":"Pay","year":"2009","journal-title":"Clin Exp Rheumatol"},{"key":"R28-85-20210309","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1007\/s00417-006-0346-y","article-title":"Results of interferon-alfa therapy in patients with Behcet uveitis.","volume":"244","author":"Tugal-Tutkun","year":"2006","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R29-85-20210309","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1002\/art.27581","article-title":"Long-term remission after cessation of interferon- treatment in patients with severe uveitis due to Behcets disease.","volume":"62","author":"Deuter","year":"2010","journal-title":"Arthritis Rheum"},{"key":"R30-85-20210309","first-page":"S20","article-title":"Cytokines, cytokine antagonists and soluble adhesion molecules in patients with ocular Behcets disease treated with human recombinant interferon-alpha2a. Results of an open study and review of the literature.","volume":"23","author":"Kotter","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"R31-85-20210309","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0923-1811(95)00439-4","article-title":"Interleukin-6 (IL-6) in patients with Behcets disease.","volume":"11","author":"Yamakawa","year":"1996","journal-title":"J Dermatol Sci"},{"key":"R32-85-20210309","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1042\/bj20030407","article-title":"Principles of interleukin (IL)-6-type cytokine signalling and its regulation.","volume":"374","author":"Heinrich","year":"2003","journal-title":"Biochem J"},{"key":"R33-85-20210309","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.cyto.2008.10.007","article-title":"Interleukin-6 in neuro-Behcets disease: association with disease subsets and long-term outcome.","volume":"44","author":"Akman-Demir","year":"2008","journal-title":"Cytokine"},{"key":"R34-85-20210309","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1007\/s10067-014-2589-z","article-title":"Paradoxical mucocutaneous flare in a case of Behcets disease treated with tocilizumab.","volume":"34","author":"Cantarini","year":"2015","journal-title":"Clin Rheumatol"},{"key":"R35-85-20210309","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0022-1759(96)00220-7","article-title":"Use of the acute phase serum amyloid A2 (SAA2) gene promoter in the analysis of pro- and anti-inflammatory mediators: differential kinetics of SAA2 promoter induction by IL-1 beta and TNF-alpha compared to IL-6.","volume":"203","author":"Uhlar","year":"1997","journal-title":"J Immunol Methods"},{"key":"R36-85-20210309","doi-asserted-by":"crossref","first-page":"3186","DOI":"10.1073\/pnas.91.8.3186","article-title":"Expression of apolipoprotein serum amyloid A mRNA in human atherosclerotic lesions and cultured vascular cells: implications for serum amyloid A function.","volume":"91","author":"Meek","year":"1994","journal-title":"Proc Natl Acad Sci USA"},{"key":"R37-85-20210309","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1046\/j.1365-3083.2000.00734.x","article-title":"Serum amyloid A secretion from monocytic leukaemia cell line THP-1 and cultured human peripheral monocytes.","volume":"52","author":"Yamada","year":"2000","journal-title":"Scand J Immunol"},{"key":"R38-85-20210309","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.atherosclerosis.2009.05.007","article-title":"Serum amyloid A induction of cytokines in monocytesmacrophages and lymphocytes.","volume":"207","author":"Song","year":"2009","journal-title":"Atherosclerosis"},{"key":"R39-85-20210309","doi-asserted-by":"crossref","first-page":"e96703","DOI":"10.1371\/journal.pone.0096703","article-title":"Serum amyloid A induces NLRP-3-mediated IL-1 secretion in neutrophils.","volume":"9","author":"Migita","year":"2014","journal-title":"PLoS One"},{"key":"R40-85-20210309","doi-asserted-by":"crossref","first-page":"6119","DOI":"10.4049\/jimmunol.1002843","article-title":"Serum amyloid A activates the NLRP3 inflammasome via P2X7 receptor and a cathepsin B-sensitive pathway.","volume":"186","author":"Niemi","year":"2011","journal-title":"J Immunol"},{"key":"R41-85-20210309","doi-asserted-by":"crossref","first-page":"R119","DOI":"10.1186\/ar3849","article-title":"Serum amyloid A triggers the mosodium urate -mediated mature interleukin-1 production from human synovial fibroblasts.","volume":"14","author":"Migita","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"R42-85-20210309","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1182\/blood-2002-05-1431","article-title":"Serum amyloid A induces IL-8 secretion through a G protein-coupled receptor, FPRL1LXA4R.","volume":"101","author":"He","year":"2003","journal-title":"Blood"},{"key":"R43-85-20210309","doi-asserted-by":"crossref","first-page":"6427","DOI":"10.4049\/jimmunol.0902941","article-title":"Acute serum amyloid A induces migration, angiogenesis, and inflammation in synovial cells in vitro and in a human rheumatoid arthritisSCID mouse chimera model.","volume":"184","author":"Connolly","year":"2010","journal-title":"J Immunol"},{"key":"R44-85-20210309","first-page":"1","article-title":"Safety issues and concerns of new immunomodulators in rheumatology.","volume":"18","author":"Selmi","year":"2014","journal-title":"Expert Opin Drug Saf"},{"key":"R45-85-20210309","doi-asserted-by":"crossref","first-page":"107421","DOI":"10.1155\/2014\/107421","article-title":"Biological treatments in Behcets disease: beyond anti-TNF therapy.","volume":"2014","author":"Caso","year":"2014","journal-title":"Mediators Inflamm"},{"key":"R46-85-20210309","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1159\/000358125","article-title":"Inhibition of interleukin-1 by canakinumab as a successful mono-drug strategy for the treatment of refractory Behcets disease: a case series.","volume":"228","author":"Vitale","year":"2014","journal-title":"Dermatology"},{"key":"R47-85-20210309","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1007\/s10067-013-2443-8","article-title":"Anakinra treatment in drug-resistant Behcets disease: a case series.","volume":"34","author":"Cantarini","year":"2015","journal-title":"Clin Rheumatol"},{"key":"R48-85-20210309","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.2174\/0929867322666150209161448","article-title":"Currently used biologic agents in the management of Behcets syndrome.","volume":"22","author":"Saygin","year":"2015","journal-title":"Curr Med Chem"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000001858","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T02:52:36Z","timestamp":1620960756000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201510030-00085"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":48,"journal-issue":{"issue":"42","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000001858","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2015,10]]}}}